COVID-19 vaccines: authorised
2. Dezember 2022 – The EMA published the assessment report for Spikevax supporting its extension of indication for use in children aged 6 months to 5 years.
For more information, see here.
2. Dezember 2022 – The EMA published the assessment report for Spikevax supporting its extension of indication for use in children aged 6 months to 5 years.
For more information, see here.